瑞普生物
(300119)
| 流通市值：54.32亿 | | | 总市值：75.66亿 |
| 流通股本：3.34亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 826,126,074.24 | 3,398,458,452.83 | 2,544,325,031.33 | 1,707,587,656.8 |
| 营业收入 | 826,126,074.24 | 3,398,458,452.83 | 2,544,325,031.33 | 1,707,587,656.8 |
| 二、营业总成本 | 704,661,498.03 | 3,020,087,411.56 | 2,202,944,319.05 | 1,464,234,653.83 |
| 营业成本 | 497,907,185.78 | 1,995,662,711.33 | 1,475,882,995 | 989,391,177.59 |
| 税金及附加 | 8,142,841.64 | 28,019,597.7 | 19,339,952.64 | 13,987,702.16 |
| 销售费用 | 96,171,383.81 | 503,814,789.02 | 366,424,397.96 | 235,038,147.08 |
| 管理费用 | 48,489,451.57 | 204,913,175.43 | 157,658,513.48 | 103,829,285.28 |
| 研发费用 | 45,325,880.26 | 253,019,299.62 | 157,025,388.67 | 104,020,978.37 |
| 财务费用 | 8,624,754.97 | 34,657,838.46 | 26,613,071.3 | 17,967,363.35 |
| 其中:利息费用 | 8,160,574.95 | 35,158,001.14 | 27,216,420.24 | 18,361,731.74 |
| 其中:利息收入 | 588,793.52 | 2,489,936.51 | 1,854,734.55 | 1,252,878.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,394,555.81 | 75,831,147.54 | 44,482,336.25 | 43,282,384.88 |
| 加:投资收益 | 9,058,766.74 | 34,221,849.5 | 59,907,276.57 | 32,094,818.1 |
| 资产处置收益 | - | 3,819,392.15 | 3,761,700.78 | 3,729,955.17 |
| 资产减值损失(新) | 21,895.03 | -6,845,074.75 | 373,473.73 | 373,473.73 |
| 信用减值损失(新) | -10,386,586.72 | -34,589,852.5 | -22,398,851.25 | -20,748,539.02 |
| 其他收益 | 4,051,948.12 | 28,776,416.74 | 14,765,085.85 | 10,040,094.62 |
| 四、营业利润 | 128,605,155.19 | 479,584,919.95 | 442,271,734.21 | 312,125,190.45 |
| 加:营业外收入 | 191,121.65 | 2,294,049.6 | 2,123,280.3 | 1,961,830.86 |
| 减:营业外支出 | 332,832.89 | 11,188,338.23 | 3,885,697.25 | 2,577,767.85 |
| 五、利润总额 | 128,463,443.95 | 470,690,631.32 | 440,509,317.26 | 311,509,253.46 |
| 减:所得税费用 | 11,054,602.15 | 36,221,382.29 | 49,717,760.09 | 39,445,666.57 |
| 六、净利润 | 117,408,841.8 | 434,469,249.03 | 390,791,557.17 | 272,063,586.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 117,408,841.8 | 434,469,249.03 | 390,791,557.17 | 272,063,586.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 107,778,219.26 | 400,513,483.64 | 362,307,052.9 | 256,522,468.88 |
| 少数股东损益 | 9,630,622.54 | 33,955,765.39 | 28,484,504.27 | 15,541,118.01 |
| 扣除非经常损益后的净利润 | 95,468,233.84 | 304,522,472.61 | 269,277,854.2 | 187,741,091.62 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 0.88 | 0.8 | 0.56 |
| (二)稀释每股收益 | 0.24 | 0.88 | 0.8 | 0.56 |
| 八、其他综合收益 | - | 45,528.73 | - | - |
| 归属于母公司股东的其他综合收益 | - | 45,528.73 | - | - |
| 九、综合收益总额 | 117,408,841.8 | 434,514,777.76 | 390,791,557.17 | 272,063,586.89 |
| 归属于母公司股东的综合收益总额 | 107,778,219.26 | 400,559,012.37 | 362,307,052.9 | 256,522,468.88 |
| 归属于少数股东的综合收益总额 | 9,630,622.54 | 33,955,765.39 | 28,484,504.27 | 15,541,118.01 |
| 公告日期 | 2026-04-28 | 2026-03-31 | 2025-10-25 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |